Advertisement

Anti-VEGF Therapy for AMD: Results and Guidelines

  • P. MitchellEmail author
  • S. Foran
Chapter

Abstract

Three recent guidelines have addressed management of neovascular AMD (NV-AMD) with anti-VEGF agents, covering diagnosis, selection including classification of lesions as ‘active’ or ‘inactive’, and approaches to treatment with anti-VEGF agents, using monthly or flexible regimens. Most data from large randomised clinical trials has accumulated for ranibizumab therapy.

Keywords

Visual Acuity Polypoidal Choroidal Vasculopathy Central Retinal Thickness Retinal Angiomatous Proliferation Visual Acuity Improvement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT (1998) Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 116:653–658PubMedGoogle Scholar
  2. 2.
    Congdon N, O’Colmain B, Klaver CC et al (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477–485PubMedCrossRefGoogle Scholar
  3. 3.
    Cotter SA, Varma R, Ying-Lai M, Azen SP, Klein R (2006) Causes of low vision and blindness in adult Latinos: the Los Angeles Latino Eye Study. Ophthalmology 113:1574–1582PubMedCrossRefGoogle Scholar
  4. 4.
    Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606–2617PubMedCrossRefGoogle Scholar
  5. 5.
    Attebo K, Mitchell P, Smith W (1996) Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 103:357–364PubMedGoogle Scholar
  6. 6.
    Wald KJ, Elsner AE, Wolf S, Staurenghi G, Weiter JJ (1994) Indocyanine green videoangiography for the imaging of choroidal neovascularization associated with macular degeneration. Int Ophthalmol Clin 34:311–325PubMedCrossRefGoogle Scholar
  7. 7.
    Kawasaki R, Yasuda M, Song SJ et al (2010) The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 117:921–927PubMedCrossRefGoogle Scholar
  8. 8.
    Bird AC, Bressler NM, Bressler SB et al (1995) An international classification and grading system for age- related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367–374PubMedCrossRefGoogle Scholar
  9. 9.
    Taylor HR, Pezzullo ML, Keeffe JE (2006) The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 90:272–275PubMedCrossRefGoogle Scholar
  10. 10.
    Hageman GS, Anderson DH, Johnson LV et al (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102:7227–7232PubMedCrossRefGoogle Scholar
  11. 11.
    Hadley D, Orlin A, Brown G et al (2010) Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26. Invest Ophthalmol Vis Sci 51:2191–2196PubMedCrossRefGoogle Scholar
  12. 12.
    Seddon JM, Gensler G, Rosner B (2010) C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology 117:1560–1566PubMedCrossRefGoogle Scholar
  13. 13.
    Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr (2009) Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 93:610–613PubMedCrossRefGoogle Scholar
  14. 14.
    Teper SJ, Nowinska A, Pilat J, Palucha A, Wylegala E (2010) Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 16:2598–2604PubMedGoogle Scholar
  15. 15.
    Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A (2007) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114:2168–2173PubMedCrossRefGoogle Scholar
  16. 16.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859–870PubMedCrossRefGoogle Scholar
  17. 17.
    Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331–371PubMedCrossRefGoogle Scholar
  18. 18.
    Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27:372–390PubMedCrossRefGoogle Scholar
  19. 19.
    Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816PubMedCrossRefGoogle Scholar
  20. 20.
    Sivaprasad S, Hykin P, Saeed A et al (2010) Intravitreal pegap­tanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience. Eye (Lond) 24:793–798CrossRefGoogle Scholar
  21. 21.
    Blick SK, Keating GM, Wagstaff AJ (2007) Ranibizumab. Drugs 67:1199–1206PubMedCrossRefGoogle Scholar
  22. 22.
    Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRefGoogle Scholar
  23. 23.
    Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444PubMedCrossRefGoogle Scholar
  24. 24.
    Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335PubMedGoogle Scholar
  25. 25.
    Rosenfeld PJ (2006) Intravitreal avastin: the low cost alternative to lucentis? Am J Ophthalmol 142:141–143PubMedCrossRefGoogle Scholar
  26. 26.
    Ip MS, Scott IU, Brown GC et al (2008) Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 115:1837–1846PubMedCrossRefGoogle Scholar
  27. 27.
    Tufail A, Patel PJ, Egan C et al (2010) Bevacizumab for neo­vascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 340:c2459PubMedCrossRefGoogle Scholar
  28. 28.
    Fong DS, Custis P, Howes J, Hsu JW (2010) Intravitreal bevacizumab and ranibizumab for age-related macular dege­neration a multicenter, retrospective study. Ophthalmology 117:298–302PubMedCrossRefGoogle Scholar
  29. 29.
    Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S (2010) Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond) 24:816–824CrossRefGoogle Scholar
  30. 30.
    Dixon JA, Oliver SC, Olson JL, Mandava N (2009) VEGF Trap-Eye for the treatment of neovascular age-related ­macular degeneration. Expert Opin Investig Drugs 18:1573–1580PubMedCrossRefGoogle Scholar
  31. 31.
    Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M (2010) Antivascular endothelial growth factors in age-related macular degeneration. Dev Ophthalmol 46:21–38PubMedCrossRefGoogle Scholar
  32. 32.
    American Academy of Ophthalmology (2011) Age-related macular degeneration summary benchmarks for Preferred Practice Pattern Guidelines 2010, pp 1–3Google Scholar
  33. 33.
    Mitchell P, Korobelnik JF, Lanzetta P et al (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2–13PubMedCrossRefGoogle Scholar
  34. 34.
    The Royal College of Ophthalmologists (2009) Age-related macular degeneration guidelines for management, pp 1–113Google Scholar
  35. 35.
    Schmidt-Erfurth UM, Richard G, Augustin A et al (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486–494PubMedCrossRefGoogle Scholar
  36. 36.
    International Council of Ophthalmology (2007) Age-related macular degeneration (management recommendations)Google Scholar
  37. 37.
    Chakravarthy U, Soubrane G, Bandello F et al (2006) Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthal­mol 90:1188–1196PubMedCrossRefGoogle Scholar
  38. 38.
    Amoaku WM (2008) The Royal College of Ophthalmologists interim recommendations for the management of patients with age-related macular degeneration. Eye (Lond) 22:864–868CrossRefGoogle Scholar
  39. 39.
    Amoaku W (2009) Ranibizumab: the clinician’s guide to commencing, continuing, and discontinuing treatment. Eye (Lond) 23:2140–2142CrossRefGoogle Scholar
  40. 40.
    Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I (1982) New visual acuity charts for clinical research. Am J Ophthalmol 94:91–96PubMedGoogle Scholar
  41. 41.
    Falkenstein IA, Cochran DE, Azen SP et al (2008) Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts. Ophthalmology 115:319–323PubMedCrossRefGoogle Scholar
  42. 42.
    Kronmal RA, Cain KC, Ye Z, Omenn GS (1993) Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 153:1065–1073PubMedCrossRefGoogle Scholar
  43. 43.
    Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8PubMedCrossRefGoogle Scholar
  44. 44.
    Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100–110PubMedCrossRefGoogle Scholar
  45. 45.
    Yannuzzi LA, Negrao S, Iida T et al (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416–434PubMedCrossRefGoogle Scholar
  46. 46.
    Golbaz I, Ahlers C, Stock G et al (2011) Quantification of the therapeutic response of intraretinal, subretinal and subpigmentepithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 52: 1599–1605Google Scholar
  47. 47.
    Smretschnig E, Krebs I, Moussa S, Ansari-Shahrezaei S, Binder S (2010) Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. Graefes Arch Clin Exp Ophthalmol 248:1693–1698PubMedCrossRefGoogle Scholar
  48. 48.
    Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T (2010) Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 30:1390–1399PubMedCrossRefGoogle Scholar
  49. 49.
    Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:246–252PubMedCrossRefGoogle Scholar
  50. 50.
    Shona O, Gupta B, Vemala R, Sivaprasad S (2011) Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Experiment Ophthalmol 39:5–8PubMedGoogle Scholar
  51. 51.
    Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850–857PubMedCrossRefGoogle Scholar
  52. 52.
    Schmidt-Erfurth U, Eldem B, Guymer R et al (2010) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831–839PubMedCrossRefGoogle Scholar
  53. 53.
    Raja MS, Saldana M, Goldsmith C, Burton BJ (2010) Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes. Br J Ophthalmol 94:1543–1545PubMedCrossRefGoogle Scholar
  54. 54.
    Liakopoulos S, Ongchin S, Bansal A et al (2008) Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49:5048–5054PubMedCrossRefGoogle Scholar
  55. 55.
    Chang MA, Do DV, Bressler SB, Cassard SD, Gower EW, Bressler NM (2010) Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina 30:1171–1176PubMedCrossRefGoogle Scholar
  56. 56.
    McKibbin M, Papastefanou V, Matthews B, Cook H, Downey L (2010) Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration. Eye (Lond) 24:994–998CrossRefGoogle Scholar
  57. 57.
    Deissler H, Deissler H, Lang S, Lang GE (2008) VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 92:839–843PubMedCrossRefGoogle Scholar
  58. 58.
    Elman MJ, Fine SL, Murphy RP, Patz A, Auer C (1986) The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. Ophthalmology 93:224–230PubMedGoogle Scholar
  59. 59.
    Bakri SJ, Kitzmann AS (2007) Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 143:505–507PubMedCrossRefGoogle Scholar
  60. 60.
    Chang LK, Sarraf D (2007) Tears of the retinal pigment epithelium: an old problem in a new era. Retina 27:523–534PubMedCrossRefGoogle Scholar
  61. 61.
    Singh RP, Kaiser PK (2007) Role of ranibizumab in management of macular degeneration. Indian J Ophthalmol 55:421–425PubMedCrossRefGoogle Scholar
  62. 62.
    Ronan SM, Yoganathan P, Chien FY et al (2007) Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 27:535–540PubMedCrossRefGoogle Scholar
  63. 63.
    Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D (2008) Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 36:252–256PubMedCrossRefGoogle Scholar
  64. 64.
    Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU, Inhoffen W (2009) Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye (Lond) 23:694–702CrossRefGoogle Scholar
  65. 65.
    Chan CK, Abraham P, Meyer CH et al (2010) Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 30:203–211PubMedCrossRefGoogle Scholar
  66. 66.
    Klein BEK, Klein R (1982) Cataracts and macular degeneration in older Americans. Arch Ophthalmol 100:571–573PubMedCrossRefGoogle Scholar
  67. 67.
    Verbraak FD, vd Berg W, Delleman JW, Greve EL (1994) Goniodysgenesis in familial primary open-angle glaucoma. Acta Ophthalmol (Copenh) 72:98–102CrossRefGoogle Scholar
  68. 68.
    Dielemans I, Vingerling JR, Hofman A, Grobbee DE, de Jong PT (1994) Reliability of intraocular pressure measurement with the Goldmann applanation tonometer in epidemiological studies. Graefes Arch Clin Exp Ophthalmol 232:141–144PubMedCrossRefGoogle Scholar
  69. 69.
    Gupta B, Adewoyin T, Patel SK, Sivaprasad S (2011) Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Br J Ophthalmol 95:386–390PubMedCrossRefGoogle Scholar
  70. 70.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE (2009) Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 147:831–837PubMedCrossRefGoogle Scholar
  71. 71.
    Querques G, Azrya S, Martinelli D et al (2010) Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 94:292–296PubMedCrossRefGoogle Scholar
  72. 72.
    Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 145:239–248PubMedCrossRefGoogle Scholar
  73. 73.
    Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315–324.e1PubMedCrossRefGoogle Scholar
  74. 74.
    Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583PubMedCrossRefGoogle Scholar
  75. 75.
    Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43–58PubMedCrossRefGoogle Scholar
  76. 76.
    Kumar A, Sahni JN, Stangos AN, Campa C, Harding SP (2011) Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol 95:530–533PubMedCrossRefGoogle Scholar
  77. 77.
    Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249–256PubMedCrossRefGoogle Scholar
  78. 78.
    Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 117:2134–2140PubMedCrossRefGoogle Scholar
  79. 79.
    Brown DM, Regillo CD (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627–637PubMedCrossRefGoogle Scholar
  80. 80.
    Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679–680PubMedCrossRefGoogle Scholar
  81. 81.
    Biarnes M, Mones J, Villalbi JR, Arias L (2011) As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. Eur J Ophthalmol 21:282–289PubMedCrossRefGoogle Scholar
  82. 82.
    Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN (2009) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 148:59–65PubMedCrossRefGoogle Scholar
  83. 83.
    Engelbert M, Zweifel SA, Freund KB (2010) Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 30:1368–1375PubMedCrossRefGoogle Scholar
  84. 84.
    Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA (2005) Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25:713–718PubMedCrossRefGoogle Scholar
  85. 85.
    Brown DM et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: 2-year results of ANCHOR study. Ophthal­mology 116:57–65PubMedCrossRefGoogle Scholar
  86. 86.
    Regillo et al (2007) Ranibizumab (Lucentis) in treatment of neovascular age-related macular degeneration (AMD): 2-year results of PIER study. Poster PO459 presented at the AAO 2007Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of SydneySydneyAustralia

Personalised recommendations